https://doi.org/10.4081/hmr.v2i13.483

Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
Published: June 10, 2009
Abstract Views: 226
PDF: 1197
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

SJ Proctor
support@pagepress.org
J Wilkinson
Until the advent of anti-CD20 antibody therapy, the mainstay of treatment in non-Hodgkin’s lymphoma (NHL) was standard chemotherapy. The combination of antibodies with chemotherapy has enhanced event-free and overall survival in both diffuse large B cell NHL and follicular NHL.1 With this example of combined chemo/ immunotherapy to enhance clinical response, it has been considered of interest to attempt a similar approach for T cell NHL and Hodgkin’s lymphoma (HL).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Proctor, S., & Wilkinson, J. (2009). Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.483
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).